VEDBAEK, Denmark, Nov. 1, 2010 (GLOBE NEWSWIRE) -- Exiqon A/S (Copenhagen:EXQ), a leading supplier of high-value gene expression analysis products, today announced that Dr. Alain Sewer, Phillip Morris International, R&D, Neuchatel, Switzerland, has presented data from a comprehensive validation study of the miRCURY LNA(TM) microRNA Array product line.
Dr. Sewer's data demonstrates that the LNA(TM)-enhanced capture probes secure very sensitive and specific detection of microRNAs in complex samples. The study concludes that Exiqon's miRCURY LNA(TM) microRNA Array platform outperforms similar products provided by a main competitor.
Exiqon's microRNA arrays feature Tm-normalized, LNA(TM)-enhanced capture probes, designed by advanced bioinformatics algorithms for excellent specificity and sensitivity for all microRNAs in more than 100 different species.
The miRCURY LNA(TM) microRNA Array product line includes the miRCURY LNA(TM) microRNA Arrays, miRCURY LNA(TM) microRNA Power Labeling Kits and the miRCURY LNA(TM) microRNA Array Analysis Software. The products are provided with protocols for a number of different instrument platforms.
"We are always pleased when a major international customer publishes the conclusions from their internal validation studies. In this publication, it is demonstrated that Exiqon's products are superior in terms of sensitivity and specificity which represent the most important values for our customers", said Henrik M. Pfundheller, VP Sales & Marketing at Exiqon.
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell: +45 4090 2101)
Henrik M. Pfundheller, VP Sales & Marketing, tel. +45 4565 0420 (cell: +45 4090 2106)
See the full release at